Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Woodford Woes Drag On For Immunocore

Unrealistic Valuations Holding Private Firms Back

Executive Summary

Once seen as the champion of biotech start-ups, Woodford’s blind faith has shackled firms to unrealistic valuations.

You may also be interested in...



Troubled Immunocore Reawakens With New $130m Funding

After a record breaking Series A fundraising, the UK biotech hit a series of problems. Can a new CEO and new funding help it fulfil its promise?

Autolus Faces Life After Woodford With New Czech Backer

PPF has bought a big stake in the UK-based T-cell specialist, one of many firms backed by investor Neil Woodford which have suffered stock slides in the past few months.

J&J Spots Potential Of Fate’s Stem Cells, Signs Cancer Deal Worth Up To $3bn

Investment from Janssen helps to validate the platform developed by the San Diego-based company.

Topics

Related Companies

UsernamePublicRestriction

Register

SC141638

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel